MedTrace Logo

4SC-201 (Resminostat) in Advanced Colorectal Carcinoma

NCT01277406 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2015-04-01

No results posted yet for this study

Summary

The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of 4SC-201 (Resminostat) in combination with FOLFIRI and whether 4SC-201 (Resminostat) is effective and safe in combination FOLFIRI versus FOLFIRI alone in the treatment of advanced colorectal carcinoma.

Conditions

  • Advanced Colorectal Carcinoma

Interventions

DRUG

4SC-201(Resminostat)

oral administration

DRUG

FOLFIRI

i.v. administration

Sponsors & Collaborators

  • 4SC AG

    lead INDUSTRY

Principal Investigators

  • Dirk Jäger, Prof. Dr. · Medical Oncology National Centre for Tumor Diseases (NCT); University of Heidelberg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-02-28
Completion
2015-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01277406 on ClinicalTrials.gov